Last reviewed · How we verify
BR1018A-1
BR1018A-1 is a small molecule drug that targets the renin-angiotensin system.
BR1018A-1 is a small molecule drug that targets the renin-angiotensin system. Used for Hypertension, Heart failure.
At a glance
| Generic name | BR1018A-1 |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
BR1018A-1 works by inhibiting the angiotensin-converting enzyme (ACE), which plays a key role in the renin-angiotensin system. This leads to a decrease in blood pressure and a reduction in the risk of cardiovascular events.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BR1018A-1 CI brief — competitive landscape report
- BR1018A-1 updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI